Literature DB >> 24492367

Factors that cause trimethoprim resistance in Streptococcus pyogenes.

René Bergmann1, Mark van der Linden, Gursharan S Chhatwal, D Patric Nitsche-Schmitz.   

Abstract

The use of trimethoprim in treatment of Streptococcus pyogenes infections has long been discouraged because it has been widely believed that this pathogen is resistant to this antibiotic. To gain more insight into the extent and molecular basis of trimethoprim resistance in S. pyogenes, we tested isolates from India and Germany and sought the factors that conferred the resistance. Resistant isolates were identified in tests for trimethoprim or trimethoprim-sulfamethoxazole (SXT) susceptibility. Resistant isolates were screened for the known horizontally transferable trimethoprim-insensitive dihydrofolate reductase (dfr) genes dfrG, dfrF, dfrA, dfrD, and dfrK. The nucleotide sequence of the intrinsic dfr gene was determined for resistant isolates lacking the horizontally transferable genes. Based on tentative criteria, 69 out of 268 isolates (25.7%) from India were resistant to trimethoprim. Occurring in 42 of the 69 resistant isolates (60.9%), dfrF appeared more frequently than dfrG (23 isolates; 33.3%) in India. The dfrF gene was also present in a collection of SXT-resistant isolates from Germany, in which it was the only detected trimethoprim resistance factor. The dfrF gene caused resistance in 4 out of 5 trimethoprim-resistant isolates from the German collection. An amino acid substitution in the intrinsic dihydrofolate reductase known from trimethoprim-resistant Streptococcus pneumoniae conferred resistance to S. pyogenes isolates of emm type 102.2, which lacked other aforementioned dfr genes. Trimethoprim may be more useful in treatment of S. pyogenes infections than previously thought. However, the factors described herein may lead to the rapid development and spread of resistance of S. pyogenes to this antibiotic agent.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24492367      PMCID: PMC4023743          DOI: 10.1128/AAC.02282-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Synergy of trimethoprim-sulfamethoxazole.

Authors:  S R Bushby
Journal:  Can Med Assoc J       Date:  1975-06-14       Impact factor: 8.262

2.  Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis.

Authors:  E L Kaplan; D R Johnson
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

3.  Effect of trimethoprim on macromolecular synthesis in Escherichia coli.

Authors:  M Miovic; L I Pizer
Journal:  J Bacteriol       Date:  1971-06       Impact factor: 3.490

4.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate.

Authors:  J T Bolin; D J Filman; D A Matthews; R C Hamlin; J Kraut
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

5.  Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis.

Authors:  D J Filman; J T Bolin; D A Matthews; J Kraut
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

6.  Mutations and horizontal transmission have contributed to sulfonamide resistance in Streptococcus pyogenes.

Authors:  Maria Jönsson; Katrin Ström; Göte Swedberg
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

7.  Analysis of the conjugal transfer system of the pheromone-independent highly transferable Enterococcus plasmid pMG1: identification of a tra gene (traA) up-regulated during conjugation.

Authors:  Koichi Tanimoto; Yasuyoshi Ike
Journal:  J Bacteriol       Date:  2002-10       Impact factor: 3.490

8.  Dihydrofolate reductase. The stereochemistry of inhibitor selectivity.

Authors:  D A Matthews; J T Bolin; J M Burridge; D J Filman; K W Volz; J Kraut
Journal:  J Biol Chem       Date:  1985-01-10       Impact factor: 5.157

9.  Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim.

Authors:  D A Matthews; J T Bolin; J M Burridge; D J Filman; K W Volz; B T Kaufman; C R Beddell; J N Champness; D K Stammers; J Kraut
Journal:  J Biol Chem       Date:  1985-01-10       Impact factor: 5.157

Review 10.  Recommendations for the management of beta-lactam intolerance.

Authors:  Eric Macy; Eunis Ngor
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 10.817

View more
  13 in total

1.  Diversity and Evolution of the Tn5801-tet(M)-Like Integrative and Conjugative Elements among Enterococcus, Streptococcus, and Staphylococcus.

Authors:  Ricardo León-Sampedro; Carla Novais; Luísa Peixe; Fernando Baquero; Teresa M Coque
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

2.  MRSA Isolates from United States Hospitals Carry dfrG and dfrK Resistance Genes and Succumb to Propargyl-Linked Antifolates.

Authors:  Stephanie M Reeve; Eric W Scocchera; Narendran G-Dayanadan; Santosh Keshipeddy; Jolanta Krucinska; Behnoush Hajian; Jacob Ferreira; Michael Nailor; Jeffrey Aeschlimann; Dennis L Wright; Amy C Anderson
Journal:  Cell Chem Biol       Date:  2016-12-08       Impact factor: 8.116

Review 3.  Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance.

Authors:  Shannon Lynn Kordus; Anthony David Baughn
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

Review 4.  New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.

Authors:  Michael J Durkin; G Ralph Corey
Journal:  Ther Clin Risk Manag       Date:  2015-05-22       Impact factor: 2.423

Review 5.  Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.

Authors:  Asha C Bowen; Jonathan R Carapetis; Bart J Currie; Vance Fowler; Henry F Chambers; Steven Y C Tong
Journal:  Open Forum Infect Dis       Date:  2017-11-02       Impact factor: 3.835

6.  A global to local genomics analysis of Clostridioides difficile ST1/RT027 identifies cryptic transmission events in a northern Arizona healthcare network.

Authors:  Charles H D Williamson; Nathan E Stone; Amalee E Nunnally; Heidie M Hornstra; David M Wagner; Chandler C Roe; Adam J Vazquez; Nivedita Nandurkar; Jacob Vinocur; Joel Terriquez; John Gillece; Jason Travis; Darrin Lemmer; Paul Keim; Jason W Sahl
Journal:  Microb Genom       Date:  2019-05-20

7.  Hospital outbreak caused by linezolid resistant Enterococcus faecium in Upper Austria.

Authors:  Heidrun Kerschner; Adriana Cabal; Rainer Hartl; Sigrid Machherndl-Spandl; Franz Allerberger; Werner Ruppitsch; Petra Apfalter
Journal:  Antimicrob Resist Infect Control       Date:  2019-09-09       Impact factor: 4.887

Review 8.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

Review 9.  Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

Authors:  Darrell McBride; Tamara Krekel; Kevin Hsueh; Michael J Durkin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-16       Impact factor: 4.481

10.  Rationally designing antisense therapy to keep up with evolving bacterial resistance.

Authors:  Seyfullah Kotil; Eric Jakobsson
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.